Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

E-Poster Display

1792P - French real world study on patient characteristics and treatment strategies in first-line of extensive-stage small cell lung cancer (ES SCLC)

Date

17 Sep 2020

Session

E-Poster Display

Topics

Tumour Site

Small Cell Lung Cancer

Presenters

Didier Debieuvre

Citation

Annals of Oncology (2020) 31 (suppl_4): S974-S987. 10.1016/annonc/annonc290

Authors

D. Debieuvre1, C. Dayen2, A. Dixmier3, S. Gally4, D. Pau4, W. Greenwood5, L. Falchero6

Author affiliations

  • 1 Centre Hospitalier Emile Muller, Hopital Emile Muller, 68100 - Mulhouse/FR
  • 2 Pneumology Department, Clinique de l'Europe, 80090 - Amiens/FR
  • 3 Pneumology Department, C.H.R. Orleans - La Source, 45100 - Orleans/FR
  • 4 Medical Affairs, Roche S.A.S, 92650 - Boulogne-Billancourt/FR
  • 5 Medical Affairs Oncology, Roche S.A.S, 92650 - Boulogne-Billancourt/FR
  • 6 Pneumology Department, Hospital Center De Villefranche-Sur-Saône, 69400 - Gleizé/FR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1792P

Background

The prognosis of ES SCLC has remained poor since two decades ago when the actual standard of care, cisplatin or carboplatin combined with etoposide (Cisp-E and Carb-E), was established. At the time of the first promising results of immunotherapy in this indication, our study describes patient characteristics, real world treatment strategies and the efficacy of chemotherapies that could eventually be combined with immunotherapy.

Methods

FRESC is a secondary data use study on French national lung cancer clinical databases in non-academic hospitals: KBP-2010 (7051 patients followed during 5 years) and ESCAP-2011 (3943 patients followed during 3 years). 1L ES SCLC target population was defined among both cohorts (796 at initial diagnosis = KBP; 475 at initial diagnosis + during follow-up = ESCAP) to maximize representativeness in French population. A subpopulation of patients meeting the IMpower133 trial inclusion criteria was also defined (394 = KBP IMpower-like). The primary objective was to describe baseline characteristics of patients with untreated ES SCLC.

Results

Patient characteristics were similar between KBP and ESCAP cohorts, with a majority of men (respectively 77 and 76%), similar ECOG PS 0-1 rate (59 and 60%) but differing TNM stage repartitions (stage IV = 85% and 77%). In both cohorts the Cisp-E subgroup patients were younger (median age 61 years for both) and fitter (ECOG PS 0-1 = 75 and 73%) than in the Carb-E subgroup (median age 71 and 70 years; ECOG PS 0-1 = 56 % for both). The 1st therapeutic strategy was predominantly a combination of Etoposide with platinum (Carb-E = 40% and Cisp-E = 37% in KBP; Carb-E = 40% and Cisp-E = 34% in ESCAP). In both populations, median Overall Survival (OS) with Cisp-E was 9.6 and 9.4 months, median OS with Carb-E was 7 months. Overall adjusted median OS of the 375 evaluable patients in the KBP IMpower-like population was 9.4 months (10 and 8.2 months in Cisp-E and Carb-E).

Conclusions

Characteristics and OS of 1L ES SCLC patients treated in non-academic hospitals differ depending on treatment strategy. When applying main population characteristics of IMpower133 to FRESC, efficacy results are closer to the ones that were found in IMpower133 control arm.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Roche S.A.S.

Funding

Roche S.A.S.

Disclosure

D. Debieuvre: Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Roche; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: BMS; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Pfizer; Honoraria (self), Research grant/Funding (institution), Travel/Accommodation/Expenses: AstraZeneca; Honoraria (self), Research grant/Funding (institution): Chugaï; Honoraria (self), Research grant/Funding (institution): Lilly; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Novartis; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): MSD; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Boehringer Ingelheim; Research grant/Funding (institution): Chiesi; Research grant/Funding (institution): Janssen; Research grant/Funding (institution): GSK; Research grant/Funding (institution): Sandoz; Travel/Accommodation/Expenses: MundiPharma; Travel/Accommodation/Expenses: Pierre Fabre. A. Dixmier: Honoraria (self): Roche; Honoraria (self): Novartis; Honoraria (self): BMS. S. Gally, D. Pau, W. Greenwood: Full/Part-time employment: Roche. L. Falchero: Advisory/Consultancy: Roche; Advisory/Consultancy: Boehringer; Advisory/Consultancy: AstraZeneca; Advisory/Consultancy: Pfizer; Advisory/Consultancy: Novartis; Advisory/Consultancy: Pierre Fabre; Advisory/Consultancy: BMS; Advisory/Consultancy: MSD; Advisory/Consultancy: Chiesi; Advisory/Consultancy: GSK; Advisory/Consultancy: Menarini; Advisory/Consultancy: Amgen. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.